Weekly Anesthesiology Research Analysis
This week’s anesthesiology literature highlights three high-impact directions: a mechanistic discovery (sensory neuron BRAF) that offers a drug-repurposing path to reduce opioid-induced hyperalgesia and tolerance; randomized and pragmatic trials showing neuromodulation (taVNS) can favorably alter perioperative mood and cognitive trajectories; and a large randomized trial demonstrating remimazolam increases emergence delirium relative to propofol in older thoracic surgery patients, prompting imme
Summary
This week’s anesthesiology literature highlights three high-impact directions: a mechanistic discovery (sensory neuron BRAF) that offers a drug-repurposing path to reduce opioid-induced hyperalgesia and tolerance; randomized and pragmatic trials showing neuromodulation (taVNS) can favorably alter perioperative mood and cognitive trajectories; and a large randomized trial demonstrating remimazolam increases emergence delirium relative to propofol in older thoracic surgery patients, prompting immediate reconsideration of anesthetic choice. Across the week, evidence also converged on physiologic and biomarker-enabled risk stratification and on procedure-specific anesthesia strategies that improve recovery and reduce complications.
Selected Articles
1. Sensory neuron BRAF mediates opioid-induced hyperalgesia and tolerance via presynaptic NMDA receptor hyperactivity.
Preclinical mechanistic work shows morphine induces BRAF translocation to nociceptor terminals, driving MEK-ERK signaling and presynaptic NMDAR hyperactivity; pharmacologic BRAF/MEK inhibition or DRG-specific Braf deletion reversed these changes, enhanced morphine analgesia, and reduced opioid-induced hyperalgesia and tolerance, suggesting repurposing approved BRAF inhibitors to preserve opioid efficacy.
Impact: Identifies a targetable neuronal kinase mechanism (BRAF at nociceptor terminals) directly linking opioid exposure to maladaptive plasticity, and demonstrates reversal with clinically approved inhibitor classes—opening a translational path to reduce opioid harms while preserving analgesia.
Clinical Implications: Supports early-phase clinical investigation of BRAF/MEK inhibitors (or peripherally restricted analogues) as opioid-sparing or opioid-adjunctive therapies to mitigate hyperalgesia/tolerance; careful safety and oncologic-risk assessment will be required before perioperative use.
Key Findings
- Morphine drives translocation of BRAF to dorsal root ganglion→spinal synaptosomes and increases MEK-ERK phosphorylation at nociceptor terminals.
- BRAF physically associates with NMDARs and promotes presynaptic NMDAR hyperactivity linked to hyperalgesia/tolerance.
- Vemurafenib (BRAF inhibitor) or MEK inhibition, and DRG-specific Braf knockout, reverse NMDAR hyperactivity and mitigate opioid-induced hyperalgesia/tolerance while enhancing analgesia.
2. Effectiveness of transcutaneous auricular vagus nerve stimulation in alleviating postpartum blues following cesarean delivery: A randomized double-blind controlled trial.
A double-blind RCT (n=100) found 5 days of taVNS after cesarean reduced postpartum blues severity, improved mood measures, decreased the proportion with EPDS ≥13 at 1 month (4% vs 26%), reduced postoperative pain across early timepoints, and improved sleep quality—suggesting taVNS as a low-risk perioperative adjunct with multi-domain benefits.
Impact: Rigorous sham-controlled evidence that a noninvasive neuromodulation device can concurrently improve mood, pain, and sleep in postpartum surgical patients—an area of high unmet need linking anesthesiology to maternal mental health.
Clinical Implications: Consider piloting taVNS in post-cesarean care pathways to reduce early postpartum mood disturbance and improve recovery metrics; implementation requires device access, staff training, and larger multicenter validation to confirm durability and scalability.
Key Findings
- Active taVNS reduced PPB severity on day 5 and improved Profile of Mood States and Stein Maternity Blues Scale (p<0.001).
- EPDS ≥13 at 1 month was lower with taVNS (4%) vs sham (26%; p=0.003).
- taVNS reduced postoperative pain at multiple early time points and improved sleep quality on POD 1–4.
3. Remimazolam vs. propofol anaesthesia for delirium in older patients recovering from lung resections: a randomised non-inferiority trial.
A randomized, blinded non-inferiority trial in 455 patients aged ≥65 undergoing lung resection found remimazolam was associated with higher postoperative delirium (48%) than propofol (31%), driven largely by emergence delirium; non-inferiority was not demonstrated, suggesting propofol may be preferred to reduce early delirium in this population.
Impact: Large, randomized, blinded-assessment evidence that an ultra-short benzodiazepine anesthetic (remimazolam) increases early postoperative delirium in older thoracic surgery patients—an actionable finding likely to change anesthetic selection and PACU monitoring practices.
Clinical Implications: In older patients undergoing lung resection, prefer propofol over remimazolam when aiming to minimize emergence delirium; if remimazolam is used, implement heightened PACU surveillance and nonpharmacologic delirium mitigation strategies.
Key Findings
- Delirium incidence: remimazolam 48% vs propofol 31% (risk ratio 1.53); absolute risk difference 16.5%, exceeding non-inferiority margin.
- Emergence delirium was markedly higher with remimazolam (46% vs 28%).
- Post-PACU delirium was uncommon and similar between groups; no differences in 30-day MMSE or length of stay reported in abstract.